Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of DoubleVerify Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the company overbilled customers for ad impressions served to declared bots and that its risk disclosures were materially false and misleading [5]. - The lawsuit asserts that competitors were better positioned to incorporate AI into their offerings, adversely impacting DoubleVerify's profits and competitive standing [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of DoubleVerify Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin Activation Services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also states that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and its risk disclosures were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company [4].

Core Viewpoint - A class action lawsuit has been filed against Apple Inc. for allegedly making false and misleading statements regarding the integration of advanced AI-based features into its devices, which may have impacted investor decisions and the company's financial prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Apple securities between June 10, 2024, and June 9, 2025 [1]. - The lawsuit claims that Apple misstated the timeline for integrating advanced AI-based Siri features, which were unlikely to be available for the iPhone 16, potentially harming sales [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for clients [4]. - Investors can join the class action by submitting a form or contacting the law firm directly [3][6]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7].

Core Viewpoint - Compass Diversified (NYSE: CODI) has issued a warning to investors regarding the unreliability of its financial statements for the fiscal years ending December 31, 2022 and 2023 due to expanded accounting irregularities [1][5]. Group 1: Financial Irregularities - The company disclosed that accounting irregularities at its subsidiary, Lugano Holding, have affected financial statements not only for 2024 but also for the fiscal years 2022 and 2023 [4][5]. - Investors are advised to no longer rely on the annual and quarterly financial statements for these years [5]. Group 2: Legal Actions - A class-action lawsuit has been filed against Compass Diversified, seeking to represent investors who purchased its publicly traded securities from February 24, 2022, to May 7, 2025 [3][4]. - The lawsuit alleges that the company made false and misleading statements while failing to disclose critical information regarding its financial practices [6]. Group 3: Market Reaction - Following the announcement of the accounting irregularities, Compass Diversified's stock price fell by more than 62% [7]. Group 4: Internal Controls and Oversight - The company has been criticized for neglecting to implement effective internal controls over its financial reporting, leading to materially misstated financial results [9]. - The issues at Lugano suggest a failure of oversight by Compass Diversified, indicating a deeper problem within the subsidiary [10].

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed on June 25, 2025, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety of its products and the legality of its marketing practices [4][5]. - The termination of the collaboration with Novo Nordisk was announced on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices that jeopardized patient safety [5]. Group 2: Impact on Share Price - Following the announcement of the termination, Hims & Hers shares experienced a significant decline, crashing by 30% [2]. Group 3: Investigation and Legal Support - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities between March 21, 2023, and December 9, 2024, of the July 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Bitfarms securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 8, 2025 [2] - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to inaccurate financial statements that may need to be restated [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation for alleged misleading statements and failure to disclose critical information regarding its business performance during the specified Class Period from August 13, 2024, to May 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [5]. - It is alleged that updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [5]. - The lawsuit asserts that the public statements made by 3D Systems were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased 3D Systems securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 12, 2025, to represent other class members in the litigation [3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - The firm emphasizes the importance of selecting qualified legal counsel with proven success in securities litigation [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - The investigation is prompted by a report from Grizzly Research, which claims that GeneDx is involved in widespread fraud, manipulating Medicaid and Medicare systems to inflate revenue [3]. - Following the allegations, GeneDx's stock experienced a decline of 6.7% on February 5, 2025 [3]. Group 2: Class Action Details - Shareholders who purchased GeneDx securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Backblaze, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a report from Morpheus Research that accused Backblaze of financial missteps and questionable accounting practices since its IPO in November 2021 [3]. - Following the release of the Morpheus Research report, Backblaze's stock experienced a decline of 2.1% on April 24, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Backblaze securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the Rosen Law Firm directly [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

RCKT Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, June 13, 2025 /PRNewswire/ -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, ...